Generation Bio (GBIO) Stock Price, News & Analysis $1.71 -0.06 (-3.39%) (As of 12/8/2023 08:57 PM ET) Add Compare Share Share Today's Range$1.60▼$1.9350-Day Range$0.91▼$3.3552-Week Range$0.86▼$7.35Volume688,900 shsAverage Volume392,424 shsMarket Capitalization$112.99 millionP/E RatioN/ADividend YieldN/APrice Target$8.56 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Generation Bio MarketRank™ Stock AnalysisAnalyst RatingHold2.33 Rating ScoreUpside/Downside400.4% Upside$8.56 Price TargetShort InterestBearish6.34% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.33Based on 8 Articles This WeekInsider TradingAcquiring Shares$18,000 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($1.88) to ($1.66) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.21 out of 5 starsMedical Sector335th out of 942 stocksBiotechnology Industry9th out of 41 stocks 3.2 Analyst's Opinion Consensus RatingGeneration Bio has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 2 buy ratings, 4 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $8.56, Generation Bio has a forecasted upside of 400.4% from its current price of $1.71.Amount of Analyst CoverageGeneration Bio has only been the subject of 4 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted6.34% of the float of Generation Bio has been sold short.Short Interest Ratio / Days to CoverGeneration Bio has a short interest ratio ("days to cover") of 5.4.Change versus previous monthShort interest in Generation Bio has recently increased by 76.57%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldGeneration Bio does not currently pay a dividend.Dividend GrowthGeneration Bio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for GBIO. Previous Next 1.9 News and Social Media Coverage News SentimentGeneration Bio has a news sentiment score of 0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.53 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Generation Bio this week, compared to 1 article on an average week.Search InterestOnly 6 people have searched for GBIO on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Generation Bio to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days. Previous Next 5.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Generation Bio insiders have bought more of their company's stock than they have sold. Specifically, they have bought $18,000.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders20.80% of the stock of Generation Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions95.81% of the stock of Generation Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Generation Bio are expected to grow in the coming year, from ($1.88) to ($1.66) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Generation Bio is -0.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Generation Bio is -0.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGeneration Bio has a P/B Ratio of 0.36. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Generation Bio Stock (NASDAQ:GBIO)Generation Bio Co., a genetic medicines company, develops therapies for the treatment of rare and prevalent diseases. The company provides a portfolio of programs, including programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.Read More GBIO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GBIO Stock News HeadlinesDecember 7, 2023 | finance.yahoo.comCharles Rowland Bought 179% More Shares In Generation BioDecember 6, 2023 | finance.yahoo.comDirector Rowland Charles A Jr Acquires 342,960 Shares of Generation Bio Co (GBIO)December 11, 2023 | Autonomix (Ad)How to Invest Early In the Next Potential Breakthrough Nerve-Sensing TechnologyAutonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comDecember 5, 2023 | americanbankingnews.comFY2023 EPS Estimates for Generation Bio Co. Lowered by William Blair (NASDAQ:GBIO)December 4, 2023 | americanbankingnews.comFY2023 EPS Estimates for Generation Bio Co. Increased by Analyst (NASDAQ:GBIO)November 30, 2023 | markets.businessinsider.comJMP Securities Keeps Their Hold Rating on Generation Bio (GBIO)November 29, 2023 | msn.comGeneration Bio cuts its payroll by 40 percent in latest restructuring moveNovember 29, 2023 | bizjournals.comModerna-partnered gene therapy firm to lay off 68, including two execsDecember 11, 2023 | Autonomix (Ad)How to Invest Early In the Next Potential Breakthrough Nerve-Sensing TechnologyAutonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comNovember 29, 2023 | marketwatch.comGeneration Bio Begins Strategic Reorganization, With 40% Headcount CutNovember 29, 2023 | finance.yahoo.comGeneration Bio Announces Strategic Reorganization to Extend Cash Runway for Development of ctLNP and iqDNA PlatformsNovember 11, 2023 | markets.businessinsider.comHold Rating on Generation Bio: Innovations in Immune-Quiet DNA and ctLNP Delivery System Yet Uncertain Timeline for Hemophilia A ProgramNovember 11, 2023 | markets.businessinsider.comAnalyst Upholds Buy Rating for Generation Bio Based on 3Q23 Earnings and Strong Financial HealthNovember 10, 2023 | msn.comGeneration Bio GAAP EPS of -$0.43November 9, 2023 | finance.yahoo.comGeneration Bio Reports Business Highlights and Third Quarter 2023 Financial ResultsOctober 26, 2023 | finance.yahoo.comGeneration Bio Announces Demonstration of Highly Selective T Cell Transduction In Vivo with Cell-Targeted LNP PlatformOctober 23, 2023 | msn.comJMP Securities Downgrades Generation Bio (GBIO)October 20, 2023 | markets.businessinsider.comJMP Securities downgrades Generation Bio (GBIO) to a HoldOctober 19, 2023 | msn.comTD Cowen Downgrades Generation Bio (GBIO)October 18, 2023 | finance.yahoo.comGeneration Bio Announces Breakthrough in its Non-Viral Genetic Medicine Platform with Novel “Immune-Quiet” DNASeptember 27, 2023 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Generation Bio (GBIO), Teladoc (TDOC) and Edwards Lifesciences (EW)September 19, 2023 | finance.yahoo.comGeneration Bio to Present at the Jefferies Cell & Genetic Medicine SummitSeptember 18, 2023 | finance.yahoo.comWe're Not Worried About Generation Bio's (NASDAQ:GBIO) Cash BurnAugust 16, 2023 | msn.comJP Morgan Maintains Generation Bio (GBIO) Neutral RecommendationAugust 7, 2023 | msn.comGeneration Bio: Novel But Preclinical, Interesting But Without DataAugust 7, 2023 | finanznachrichten.deGeneration Bio Co.: Generation Bio Reports Second Quarter 2023 Financial ResultsAugust 3, 2023 | msn.comWedbush Reiterates Generation Bio (GBIO) Outperform RecommendationSee More Headlines Receive GBIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Generation Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/09/2023Today12/10/2023Fiscal Year End12/31/2023Next Earnings (Estimated)2/22/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:GBIO CUSIPN/A CIK1733294 Webgenerationbio.com Phone617-655-7500FaxN/AEmployees150Year FoundedN/APrice Target and Rating Average Stock Price Target$8.56 High Stock Price Target$14.00 Low Stock Price Target$2.23 Potential Upside/Downside+400.4%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.98) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-136,640,000.00 Net MarginsN/A Pretax Margin-4,092.23% Return on Equity-47.27% Return on Assets-31.07% Debt Debt-to-Equity RatioN/A Current Ratio9.07 Quick Ratio9.07 Sales & Book Value Annual Sales$3.03 million Price / Sales37.34 Cash FlowN/A Price / Cash FlowN/A Book Value$4.75 per share Price / Book0.36Miscellaneous Outstanding Shares66,078,000Free Float52,334,000Market Cap$112.99 million OptionableNot Optionable Beta2.49 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesDr. Cameron Geoffrey McDonough M.D. (Age 53)President, CEO & Director Comp: $939.09kDr. Matthew Norkunas M.B.A. (Age 45)M.D., Chief Financial Officer Comp: $611.11kDr. Matthew Stanton Ph.D. (Age 50)Chief Scientific Officer Comp: $654.83kDr. Douglas Kerr M.B.A. (Age 56)M.D., Ph.D., Chief Medical Officer Comp: $659.1kDr. Tracy Zimmermann Ph.D. (Age 53)Chief Development Officer Comp: $622.74kDr. Mark D. Angelino Ph.D. (Age 50)Co-Founder Dr. Robert Kotin Ph.D. (Age 67)Co-Founder Ms. Antoinette Paone M.B.A. (Age 45)M.S., Chief Operating Officer Ms. Yalonda Howze J.D. (Age 51)Chief Legal Officer & Secretary Ms. Jasmin TowerSenior Vice President of People & OperationsMore ExecutivesKey CompetitorsSagimet BiosciencesNASDAQ:SGMTReviva PharmaceuticalsNASDAQ:RVPHProPhase LabsNASDAQ:PRPHOramed PharmaceuticalsNASDAQ:ORMPChimerixNASDAQ:CMRXView All CompetitorsInsiders & InstitutionsDannielle AppelhansBought 12,000 shares on 12/4/2023Total: $18,000.00 ($1.50/share)Wellington Management Group LLPBought 120,191 shares on 12/1/2023Ownership: 0.267%American Century Companies Inc.Bought 13,103 shares on 11/30/2023Ownership: 0.047%GSA Capital Partners LLPBought 42,319 shares on 11/15/2023Ownership: 0.064%FMR LLCSold 189,794 shares on 11/13/2023Ownership: 12.790%View All Insider TransactionsView All Institutional Transactions GBIO Stock Analysis - Frequently Asked Questions Should I buy or sell Generation Bio stock right now? 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Generation Bio in the last year. There are currently 4 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" GBIO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GBIO, but not buy additional shares or sell existing shares. View GBIO analyst ratings or view top-rated stocks. What is Generation Bio's stock price target for 2024? 6 brokerages have issued 1-year price objectives for Generation Bio's shares. Their GBIO share price targets range from $2.23 to $14.00. On average, they predict the company's share price to reach $8.56 in the next twelve months. This suggests a possible upside of 400.4% from the stock's current price. View analysts price targets for GBIO or view top-rated stocks among Wall Street analysts. How have GBIO shares performed in 2023? Generation Bio's stock was trading at $3.93 at the beginning of the year. Since then, GBIO shares have decreased by 56.5% and is now trading at $1.71. View the best growth stocks for 2023 here. Are investors shorting Generation Bio? Generation Bio saw a increase in short interest in November. As of November 15th, there was short interest totaling 3,090,000 shares, an increase of 76.6% from the October 31st total of 1,750,000 shares. Based on an average daily trading volume, of 569,000 shares, the days-to-cover ratio is currently 5.4 days. Currently, 6.3% of the company's shares are sold short. View Generation Bio's Short Interest. When is Generation Bio's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, February 22nd 2024. View our GBIO earnings forecast. How were Generation Bio's earnings last quarter? Generation Bio Co. (NASDAQ:GBIO) posted its quarterly earnings results on Thursday, November, 9th. The company reported ($0.43) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.51) by $0.08. The company earned $2.15 million during the quarter, compared to analysts' expectations of $2.26 million. What other stocks do shareholders of Generation Bio own? Based on aggregate information from My MarketBeat watchlists, some companies that other Generation Bio investors own include DocuSign (DOCU), NVIDIA (NVDA), Overstock.com (OSTK), Boeing (BA), Pure Storage (PSTG), Mastercard (MA), QUALCOMM (QCOM), Riot Platforms (RIOT), Twilio (TWLO) and Enphase Energy (ENPH). When did Generation Bio IPO? (GBIO) raised $126 million in an initial public offering (IPO) on Friday, June 12th 2020. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Jefferies and Cowen served as the underwriters for the IPO and Wedbush PacGrow was co-manager. Who are Generation Bio's major shareholders? Generation Bio's stock is owned by a variety of institutional and retail investors. Top institutional investors include FMR LLC (12.79%), TD Asset Management Inc (0.62%), Wellington Management Group LLP (0.27%), GSA Capital Partners LLP (0.06%), American Century Companies Inc. (0.05%) and SG Americas Securities LLC (0.02%). Insiders that own company stock include Antoinette Paone, Charles A Rowland Jr, Dannielle Appelhans, Donald William Nicholson, Douglas Kerr, Evan Spiegel, Geoff Mcdonough, Jason P Rhodes, Matthew Stanton, Phillip Samayoa and Venture Associates X L Atlas. View institutional ownership trends. How do I buy shares of Generation Bio? Shares of GBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:GBIO) was last updated on 12/11/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Generation Bio Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.